Amarin Corporation PLC

Amarin operates with a strong liquidity position, as evidenced by $134.66 million in cash and equivalents and a current ratio of 3.34, indicating the company can easily cover its short-term liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage risk. However, the company reported negative operating income of $50.17 million and a net loss of $38.80 million, indicating ongoing profitability challenges. In terms of profitability, Amarin's return on equity (ROE) is -8.45%, and its return on assets (ROA) is -5.78%, both significantly below industry norms for biotechnology firms, which typically exhibit positive returns during periods of growth or commercialization. The company's gross profit margin is 56.6%, but this is offset by high operating expenses, leading to a negative operating margin of -23.5%. Amarin's revenue is concentrated in a single therapeutic area—cardiovascular disease—specifically through its Vascepa product. The company does not disclose geographic revenue breakdowns, but its primary market is the United States, where Vascepa is marketed. This concentration increases exposure to regulatory, reimbursement, and competitive risks in the U.S. market. The company's growth trajectory is constrained by its current financial performance. Amarin reported $213.65 million in revenue, but with a negative free cash flow of $35.67 million, the company is not generating sufficient cash to fund operations or growth without external financing. Analysts have assigned a mean price target of $12.00, which is below the current market price of $14.78, suggesting limited upside potential in the near term. Amarin faces several risk factors, including the need for continued R&D investment to expand its product pipeline and the potential for dilution if the company raises additional capital. The risk assessment indicates low dilution risk, but the company's negative net income and free cash flow suggest a potential need for financing in the future. No immediate filing-based liquidity or dilution flags were detected, but the company's operating cash flow of $6.73 million is insufficient to cover its operating losses. Recent filings and transcripts indicate that Amarin is focused on maintaining Vascepa's market position and exploring new indications for the drug. The company has not disclosed any major new product candidates in the pipeline, and its reliance on a single product increases business risk.